Acorda Therapeutics Cost of Revenue 2011-2026 | ACOR

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Acorda Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
15.3 M	30.3 M	40.8 M	33.5 M	34.8 M	97.6 M	111 M	107 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
111 M	15.3 M	58.9 M

Quarterly Cost of Revenue Acorda Therapeutics

2024-Q1	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.71 M	3.23 M	-	11 M	8.8 M	5.97 M	-	13.3 M	11.3 M	12 M	-	12.2 M	6.66 M	3.84 M	-	7.99 M	9.4 M	8.8 M	-	25.2 M	30.4 M	20.6 M	-	30 M	29.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
30.4 M	3.23 M	13.4 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	421 K	$ 0.79	-1.15 %	$ 4.31 M	China
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Grifols, S.A. GRFS	2.97 B	$ 7.81	-2.01 %	$ 6.83 B	Spain
Ascendis Pharma A/S ASND	3.52 M	$ 225.98	-1.32 %	$ 5 B	Danmark
ADC Therapeutics SA ADCT	1.39 M	$ 4.13	-5.06 %	$ 105 M	Schweiz
Adverum Biotechnologies ADVM	100 K	-	-	$ 86.2 M	USA
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
BioCardia BCDA	4 K	$ 1.26	-0.79 %	$ 26.7 M	USA
Anika Therapeutics ANIK	63.6 M	$ 14.2	-0.7 %	$ 208 M	USA
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
BioNTech SE BNTX	2.91 B	$ 91.19	1.21 %	$ 27.2 B	Germany
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
AVEO Pharmaceuticals AVEO	4.74 M	-	-	$ 521 M	USA
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	20.6 M	$ 2.54	-5.22 %	$ 16 M	USA
Certara CERT	161 M	$ 6.67	1.6 %	$ 1.07 B	USA
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany